NCT00410228已完成1 期
A Single Center, Randomized, Double-Blind, Placebo-and Positive-Controlled, Interleaved, Ascending Single Dose Study to Explore the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral AHTT956 in Healthy Subjects
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- Novartis
- 入组人数
- 42
- 试验地点
- 1
- 主要终点
- Safety, tolerability of ascending single doses of AHT956 in healthy subjects
研究概览
简要总结
This study will evaluate the safety and tolerability of ascending single oral doses of AHT956 in healthy subjects
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy male and female subjects age 18 to 45 years of age included, and in good health as determined by past medical history, physical examination, vital signs, electrocardiogram, and laboratory tests at screening.
- •Vital signs must be within the following ranges: oral body temperature between 35.0-37.5 °C; systolic blood pressure, 90-145 mm Hg; diastolic blood pressure, 50-95 mm Hg; pulse rate, 40-90 bpm
- •Female subjects must either:have been surgically sterilized or hysterectomized at last 6 months prior to study participation with clinical documentation be postmenopausal (no regular menstrual bleeding for at least 1 year prior to study start)
- •Body mass index must be within the range of 18 to 28 kg/m². Subjects must weigh at least 50 kg to participate in this study.
排除标准
- •Smokers (any subject who uses tobacco or has cotinine greater than 500 ng/mL)).
- •Subjects who received live vaccine 4 weeks prior to dosing, any prescription drug use with 4 weeks prior to dosing, or over-the-counter medication use within 2 weeks prior to dosing.
- •Participation in any clinical investigation within 4 weeks prior to dosing or longer if required by local regulations, and for any other limitation of participation based on local regulations.
- •Donation or loss of 400 mL or more of blood within 8 weeks prior to first dosing, or longer if required by local regulation.
- •Flu-like symptoms or significant within two weeks prior to dosing.
- •A past medical history of clinically significant abnormality detected during electrocardiogram (ECG) examination or an evident family history (grandparents, parents and siblings) of a ECG abnormality (i.e. prolonged QT-interval syndrome).
- •History of fainting, hypotension when standing up, arrhythmia.
- •History of acute or chronic bronchospastic disease (including asthma and chronic obstructive pulmonary disease (including asthma and chronic obstructive pulmonary disease, treated or not treated).
- •History of clinically significant drug allergy or history of atopic allergy, urticaria, eczematous dermatitis). A known hypersensitivity to the study drugs or drugs similar to the study drugs.
- •Any history of surgical or medical condition(s) which could change the absorption, distribution, metabolism or excretion of drugs or which may jeopardize the subject, including history of gastrointestinal, pancreatic, liver, kidney, bladder, blood, or immune systems.
- •History of drug or alcohol abuse within the 12 months prior to dosing or evidence of such abuse as indicated by the laboratory assays conducted the screening or baseline evaluations.
- •Other protocol-defined inclusion/exclusion criteria may apply
结局指标
主要结局
Safety, tolerability of ascending single doses of AHT956 in healthy subjects
MTD (Maximum Tolerated Dose)
次要结局
- Pharmacokinetics of single oral doses of AEB071
- Inhibition of T-cell function and lymphocytes proliferation following single rising oral of AHT956
- Pharmacokinetic/pharmacodynamic relationship of single rising oral doses of AHT956 at the end of study
- Identify gene expression patterns of blood cells
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Phase 1 Study of RO6806127 in Healthy Male VolunteersHealthy VolunteerNCT02196636Hoffmann-La Roche37
已完成
1 期
A Single Centre, Phase I, Double-blind, Randomised, Placebo-controlled Study to Investigate the Safety, Tolerability, Pharmacokinetic Profile and Effects on EEG of Single Rising Oral Doses of BIA 2-093EpilepsyNCT02171195Bial - Portela C S.A.64
已完成
1 期
A Randomized, Double-Blind, Placebo-Controlled, Ascending Single Dose Study of E6007 in Healthy SubjectsInflammatory Bowel DiseaseNCT01221818Eisai Inc.48
已完成
1 期
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of AEB071HealthyNCT00409929Novartis16
已完成
1 期
Safety, Tolerability and Pharmacokinetics Study of LY03005Major Depressive DisorderNCT02055300Luye Pharma Group Ltd.88